Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 454

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Open access
Mehra, Ranee, Seiwert, Tanguy Y., Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P., Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Geva, Ravit, Chung, Hyun Cheol, Lin, Chia-Chi, Aurora-Garg, Deepti, Ray, Archana, Pathiraja, Kumudu, Cheng, Jonathan, Chow, Laura Q. M., Haddad, Robert·2018·British Journal of Cancer

Abstract

BACKGROUND: Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab for the treatment of HNSCC after long-term follow-up. METHODS: Multi-centre, non-randomised trial included two HNSCC cohorts (initial and expansion) in which 192 patients were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks (initial cohort; N = 60) or 200 mg every 3 weeks (expansion cohort; N = 132). Co-primary endpoints were safety and overall response rate (ORR; RECIST v1.1; central imaging vendor review). RESULTS: Median follow-up was 9 months (range, 0.2-32). Treatment-related adverse events (AEs) of any grade and grade 3/4 occurred in 123 (64%) and 24 (13%) patients, respectively. No deaths were attributed to treatment-related AEs. ORR was 18% (34/192; 95% CI, 13-24%). Median response duration was not reached (range, 2+ to 30+ months); 85% of responses lasted ≥6 months. Overall survival at 12 months was 38%. CONCLUSIONS: Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0131-9

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Merck & Co. Inc. KEYTRUDA® (pembrolizumab) for Injection, for Intravenous Use KEYTRUDA® (Pembrolizumab) Injection, for Intravenous Use (Merck & Co., Inc., Whitehouse Station, NJ, 2017).
  2. Agilent Technologies. Agilent technologies receives expanded FDA approval for use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in non-small cell lung cancer (NSCLC), press release, 24 October 2016, http://www.businesswire.com/news/home/20161024006586/en/Agilent-Technologies-Receives-Expanded-FDA-Approval-Dako (2016).

Cited by

See all 454

Metadata

Authors
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., Muro, K., Geva, R., Chung, H. C., Lin, C.-C., Aurora-Garg, D., Ray, A., Pathiraja, K., Cheng, J., Chow, L. Q. M., & Haddad, R.
Venue
British Journal of Cancer
Published
2018-06-29
Volume
119
Issue
2
Pages
153-159
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2811088815
Cited by
454
References
29
FWCI
37.74
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. https://app.cochat.ai/papers/10.1038/s41416-018-0131-9
The paper
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., Muro, K., Geva, R., Chung, H. C., Lin, C.-C., Aurora-Garg, D., Ray, A., Pathiraja, K., Cheng, J., Chow, L. Q. M., & Haddad, R. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0131-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.